SC
Squadron Capital Management LLC
13F filer · CIK 0002050709Reported Aug 14, 2026
Net buyer this quarter
13F portfolio value$322MU.S. long equity reported on 13F
Positions3416 new · 12 closed
Net flow last quarter+$17.2MBuys minus sells
Top 10 positions weight66.2%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Aug 14, 202634 positions | |||||
| $50.9M | 15.78% | 6.89% | -13.3% | Q4 2025 | |
| $33.6M | 10.43% | 5.86% | +220.0% | Q1 2026 | |
| $33.5M | 10.39% | 0.50% | +9.8% | Q4 2025 | |
| $19.5M | 6.05% | 0.80% | +31.6% | Q4 2025 | |
| $18.1M | 5.63% | 0.44% | +44.2% | Q1 2026 | |
| $17.9M | 5.57% | 5.16% | +1.9% | Q1 2026 | |
| $11.8M | 3.66% | 0.27% | -17.1% | Q4 2025 | |
| $10M | 3.10% | 0.60% | +30.1% | Q4 2025 | |
| $9.2M | 2.86% | 1.26% | +355.1% | Q4 2025 | |
| $8.8M | 2.73% | Not reported | -39.6% | Q1 2026 | |
| $8.12M | 2.52% | 0.22% | New | Q2 2026 | |
| $6.27M | 1.95% | 1.73% | Not reported | Q4 2025 | |
| $6.09M | 1.89% | 2.27% | -14.3% | Q4 2025 | |
| $5.25M | 1.63% | 2.11% | New | Q2 2026 | |
| FBFBRXForte Biosciences, Inc. | $4.78M | 1.48% | 1.10% | New | Q2 2026 |
| $4.48M | 1.39% | 2.77% | New | Q2 2026 | |
| $4.4M | 1.36% | 0.81% | New | Q2 2026 | |
| $4.28M | 1.33% | 3.62% | Not reported | Q1 2026 | |
| $4.26M | 1.32% | 1.13% | New | Q2 2026 | |
| $4.25M | 1.32% | 0.22% | Not reported | Q4 2025 | |
| $4M | 1.24% | 0.06% | New | Q2 2026 | |
| $3.86M | 1.20% | 1.87% | +67.7% | Q1 2026 | |
| $3.8M | 1.18% | 0.34% | New | Q2 2026 | |
| $3.08M | 0.96% | 7.61% | -20.4% | Q1 2026 | |
| $2.81M | 0.87% | 1.43% | New | Q2 2026 | |
| $2.1M | 0.65% | 0.42% | New | Q2 2026 | |
| $2.07M | 0.64% | 9.83% | +80.0% | Q4 2025 | |
| $1.58M | 0.49% | 0.96% | New | Q2 2026 | |
| $1.28M | 0.40% | 4.05% | New | Q2 2026 | |
| $734K | 0.23% | 3.97% | New | Q2 2026 | |
| $515K | 0.16% | 2.99% | -52.4% | Q4 2025 | |
| $504K | 0.16% | 6.09% | New | Q2 2026 | |
| $170K | 0.05% | 0.05% | New | Q2 2026 | |
| $103K | 0.03% | 1.58% | -75.7% | Q4 2025 | |
| Q1 2026Reported May 15, 202630 positions | |||||
| $59M | 21.61% | 8.08% | +26.5% | Q4 2025 | |
| $30.3M | 11.11% | 0.46% | +1.0% | Q4 2025 | |
| KPKALVKalVista Pharmaceuticals, Inc. | $19.8M | 7.27% | 1.92% | +40.7% | Q4 2025 |
| $14.5M | 5.31% | 0.61% | +30.3% | Q4 2025 | |
| $14.5M | 5.30% | 0.17% | -10.3% | Q4 2025 | |
| $11M | 4.04% | 0.33% | Not reported | Q4 2025 | |
| $8.99M | 3.30% | 0.61% | New | Q1 2026 | |
| $8.76M | 3.21% | Not reported | New | Q1 2026 | |
| $8.5M | 3.11% | 5.10% | New | Q1 2026 | |
| $7.69M | 2.82% | 0.52% | -47.5% | Q4 2025 | |
| $6.98M | 2.56% | 12.26% | New | Q1 2026 | |
| $6.69M | 2.45% | 0.36% | New | Q1 2026 | |
| $5.92M | 2.17% | 2.16% | New | Q1 2026 | |
| $5.88M | 2.15% | 2.65% | -17.2% | Q4 2025 | |
| $5.25M | 1.92% | 1.79% | -33.3% | Q4 2025 | |
| $4.92M | 1.80% | 1.31% | +36.0% | Q4 2025 | |
| $4.57M | 1.67% | 0.52% | +3.2% | Q4 2025 | |
| $4.13M | 1.51% | 3.62% | New | Q1 2026 | |
| $3.6M | 1.32% | 6.02% | -15.1% | Q4 2025 | |
| $2.97M | 1.09% | 0.28% | +78.3% | Q4 2025 | |
| $2.93M | 1.07% | 1.06% | New | Q1 2026 | |
| $2.88M | 1.06% | 1.20% | New | Q1 2026 | |
| $2.83M | 1.04% | 7.35% | +11.8% | Q4 2025 | |
| $2.46M | 0.90% | 1.11% | New | Q1 2026 | |
| $1.56M | 0.57% | 8.42% | Not reported | Q4 2025 | |
| $936K | 0.34% | 5.04% | -28.3% | Q4 2025 | |
| $849K | 0.31% | 3.63% | New | Q1 2026 | |
| $797K | 0.29% | 0.89% | -82.6% | Q4 2025 | |
| $469K | 0.17% | 1.16% | New | Q1 2026 | |
| $312K | 0.11% | 1.43% | New | Q1 2026 | |
| Q4 2025Reported Feb 17, 202629 positions | |||||
| $32.4M | 13.71% | 9.14% | New | Q4 2025 | |
| $27.7M | 11.74% | 0.48% | New | Q4 2025 | |
| $20.3M | 8.60% | 0.99% | New | Q4 2025 | |
| $19.6M | 8.29% | 0.18% | New | Q4 2025 | |
| KPKALVKalVista Pharmaceuticals, Inc. | $11.3M | 4.79% | 1.38% | New | Q4 2025 |
| $10.6M | 4.48% | 2.82% | New | Q4 2025 | |
| $8.69M | 3.68% | 0.33% | New | Q4 2025 | |
| $8.66M | 3.67% | 3.21% | New | Q4 2025 | |
| $8.16M | 3.46% | 0.47% | New | Q4 2025 | |
| TPTERNTerns Pharmaceuticals, Inc. | $7.68M | 3.25% | 0.17% | New | Q4 2025 |
| $6.55M | 2.78% | 0.19% | New | Q4 2025 | |
| $6.26M | 2.65% | 0.43% | New | Q4 2025 | |
| $6.1M | 2.58% | 5.10% | New | Q4 2025 | |
| $4.73M | 2.00% | 0.13% | New | Q4 2025 | |
| $4.6M | 1.95% | 0.14% | New | Q4 2025 | |
| $4.29M | 1.82% | 2.43% | New | Q4 2025 | |
| $4.26M | 1.80% | 8.61% | New | Q4 2025 | |
| $4.16M | 1.76% | 0.07% | New | Q4 2025 | |
| $4M | 1.70% | 0.51% | New | Q4 2025 | |
| $3.78M | 1.60% | 0.96% | New | Q4 2025 | |
| VBVTYXVentyx Biosciences, Inc. | $3.7M | 1.57% | 0.57% | New | Q4 2025 |
| $3.36M | 1.42% | 6.76% | New | Q4 2025 | |
| $2.98M | 1.26% | 0.09% | New | Q4 2025 | |
| $2.71M | 1.15% | 9.09% | New | Q4 2025 | |
| $2.68M | 1.14% | 0.40% | New | Q4 2025 | |
| $2.36M | 1.00% | 0.70% | New | Q4 2025 | |
| $1.4M | 0.59% | 0.16% | New | Q4 2025 | |
| $806K | 0.34% | 7.87% | New | Q4 2025 | |
| $400K | 0.17% | 0.21% | New | Q4 2025 | |
Premium opens every quarter this fund has filed